NasdaqGS:DNLIBiotechs
Will Denali Therapeutics' (DNLI) US$275 Million Tividenofusp Royalty Deal Change Its Investment Narrative?
In recent days, Denali Therapeutics and Royalty Pharma announced a US$275 million synthetic royalty funding deal tied to potential future net sales of Denali’s investigational Hunter syndrome therapy, tividenofusp alfa, with US$200 million payable at closing and another US$75 million contingent on European approval by the end of 2029.
The agreement, which depends on FDA accelerated approval by April 2026, gives Denali substantial non-dilutive capital while signaling external confidence in...